EA202090705A1 - Способы и композиции, предназначенные для лечения хронических заболеваний легких - Google Patents

Способы и композиции, предназначенные для лечения хронических заболеваний легких

Info

Publication number
EA202090705A1
EA202090705A1 EA202090705A EA202090705A EA202090705A1 EA 202090705 A1 EA202090705 A1 EA 202090705A1 EA 202090705 A EA202090705 A EA 202090705A EA 202090705 A EA202090705 A EA 202090705A EA 202090705 A1 EA202090705 A1 EA 202090705A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
treatment
chronic lung
methods
lung diseases
Prior art date
Application number
EA202090705A
Other languages
English (en)
Inventor
Норман Бартон
Александра Манджили
Original Assignee
Шайр Хьюман Дженетик Терапиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шайр Хьюман Дженетик Терапиз, Инк. filed Critical Шайр Хьюман Дженетик Терапиз, Инк.
Publication of EA202090705A1 publication Critical patent/EA202090705A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

В настоящем изобретении представлены способы и композиции, предназначенные для лечения хронического заболевания легких (CLD), предусматривающие введение нуждающемуся в лечении субъекту композиции, содержащей инсулин-подобный фактор роста-1 (IGF-1).
EA202090705A 2017-09-11 2018-09-11 Способы и композиции, предназначенные для лечения хронических заболеваний легких EA202090705A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762557113P 2017-09-11 2017-09-11
PCT/US2018/050427 WO2019051474A1 (en) 2017-09-11 2018-09-11 METHODS AND COMPOSITIONS FOR TREATING CHRONIC PULMONARY DISEASES

Publications (1)

Publication Number Publication Date
EA202090705A1 true EA202090705A1 (ru) 2020-06-11

Family

ID=63794620

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090705A EA202090705A1 (ru) 2017-09-11 2018-09-11 Способы и композиции, предназначенные для лечения хронических заболеваний легких

Country Status (19)

Country Link
US (2) US20190151411A1 (ru)
EP (1) EP3681602A1 (ru)
JP (2) JP2020533344A (ru)
KR (1) KR20200097679A (ru)
CN (1) CN111432881A (ru)
AU (1) AU2018328827A1 (ru)
BR (1) BR112020004760A2 (ru)
CA (1) CA3075482A1 (ru)
CL (1) CL2020000597A1 (ru)
CO (1) CO2020004244A2 (ru)
EA (1) EA202090705A1 (ru)
EC (1) ECSP20055797A (ru)
IL (1) IL273174A (ru)
MX (1) MX2020002744A (ru)
PE (1) PE20201166A1 (ru)
PH (1) PH12020500489A1 (ru)
SG (1) SG11202002088TA (ru)
WO (1) WO2019051474A1 (ru)
ZA (1) ZA202001568B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230113287A (ko) * 2020-10-19 2023-07-28 오크 힐 바이오 리미티드 신생아에 사용하기에 적합한 조성물
WO2023213908A1 (en) * 2022-05-04 2023-11-09 Oak Hill Bio Limited Combination therapy for preterm infants
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
EP0308500B1 (en) 1987-04-06 1993-06-16 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
JPH03504597A (ja) 1988-04-12 1991-10-09 シナージェン，インコーポレーテッド インスリン様成長因子活性の強化および阻害方法
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
AU4238493A (en) 1992-05-08 1993-12-13 Thomas Jefferson University IGF-1 analogs
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
WO2002043578A2 (en) * 2000-11-28 2002-06-06 Children's Medical Center Corporation Determination of risk and treatment of complications of prematurity
WO2008130315A1 (en) * 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity

Also Published As

Publication number Publication date
KR20200097679A (ko) 2020-08-19
PE20201166A1 (es) 2020-10-28
ZA202001568B (en) 2023-09-27
CN111432881A (zh) 2020-07-17
IL273174A (en) 2020-04-30
AU2018328827A1 (en) 2020-04-02
WO2019051474A1 (en) 2019-03-14
BR112020004760A2 (pt) 2020-09-15
JP2023145646A (ja) 2023-10-11
PH12020500489A1 (en) 2021-02-22
CL2020000597A1 (es) 2020-12-04
EP3681602A1 (en) 2020-07-22
ECSP20055797A (es) 2020-10-30
JP2020533344A (ja) 2020-11-19
CA3075482A1 (en) 2019-03-14
US20220088132A1 (en) 2022-03-24
SG11202002088TA (en) 2020-04-29
MX2020002744A (es) 2020-10-01
CO2020004244A2 (es) 2020-05-29
US20190151411A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
EA202091118A1 (ru) Антибактериальные соединения
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA201992626A1 (ru) Способы и композиции для лечения аллергических заболеваний глаз
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX2019002382A (es) Anticuerpos anti-gremlin-1 (grem1) y metodos de uso de los mismos para tratar la hipertension arterial pulmonar.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA202090164A1 (ru) Изотретиноиновые перорально-слизистые композиции и способы их применения
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
EA202190626A3 (ru) Комбинация тразодона и габапентина для лечения боли
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
EA202190504A1 (ru) Способы лечения псориаза
EA201991502A1 (ru) Композиции на основе аминокислот и способы лечения заболеваний печени